InvestorsHub Logo
Followers 85
Posts 1581
Boards Moderated 0
Alias Born 06/06/2012

Re: xoc post# 201435

Thursday, 10/26/2017 7:37:51 PM

Thursday, October 26, 2017 7:37:51 PM

Post# of 403061
Nice - scanned. Saw a mention of Brilacidin... Have always though a Big Rx w a Big Budget could truly have fun w HDP-Ms. Per below, in the summary / conclusion section.

PYMX had, and now IPIX is adding to, lots of published data on HDP-Ms as antibacterials, antifungals, antimalarials, antiTB.

Where IPIX gets most credit imo is seeing the B / the class as much as an anti-inflammatory as antibacterial and going the non systemic, route.

B IBD (oral) and B Derm (topical) potential is huge.

Pipeline in Drug idea.

--

Moreover, antimicrobial peptidomimetics have several advantages over AMPs, including enhanced stability, cell specificity, and better tolerability. Furthermore, the synthetic flexibility of these molecules allows fast structure modifications to create novel antimicrobial peptidomimetics, having particular pharmacological properties. Finally, structure–activity relationships clear the way to establish peptidomimetic libraries, which can lead to the development of novel antimicrobial agents.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News